Alpha 2.0
Login Register
» Authors » Olivier Molinier

Olivier Molinier

Explore the profile of Olivier Molinier including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 56
Citations 5388
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Franck Morin
Denis Moro-Sibilot
Clarisse Audigier-Valette
Gerard Zalcman
Didier Debieuvre
Julien Mazieres
Virginie Westeel
Alexandra Langlais
Fabrice Barlesi
Elisabeth Quoix
Published In
J Thorac Oncol
Lung Cancer
Clin Lung Cancer
Clin Cancer Res
Lancet Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting
Falchero L, Meyer N, Molinier O, Al Freijat F, Pegliasco H, Lecuyer E, et al.
Eur J Cancer . 2024 Aug; 210:114277. PMID: 39168000
Background: The KBP studies are real-life nationwide, prospective, multicenter cohort studies of patients diagnosed with primary lung cancer that have been conducted in French non-academic public hospitals each decade since...
2.
Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer
Moro-Sibilot D, Falchero L, Ardin C, Zouak A, Molinier O, Romand P, et al.
Respir Med Res . 2024 Jun; 86:101113. PMID: 38843598
Background: Studies have shown improvement in overall survival with anti-PD1/PD-L1 molecules in combination with cisplatin/carboplatin and etoposide as a first-line treatment for Small Cell Lung Cancer (SCLC). However, first-line efficacy...
3.
A Comparative Multicenter Cohort Study Evaluating the Long-Term Influence of the Strict Lockdown during the First COVID-19 Wave on Lung Cancer Patients (ARTEMISIA Trial)
Molinier O, Guguen C, Marcq M, Chene A, Masson P, Bigot F, et al.
Cancers (Basel) . 2023 Dec; 15(24). PMID: 38136275
The consequences of the strict health restrictions during the first wave of COVID-19 on lung cancer (LC) patients are not known. This cohort study evaluated the impact of the initial...
4.
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)
Dhamelincourt E, Descourt R, Rousseau-Bussac G, Doubre H, Decroisette C, Demontrond P, et al.
Target Oncol . 2023 Nov; 18(6):905-914. PMID: 37966566
Background: Although ALK-translocated (ALK+) advanced non-small cell lung cancers (aNSCLCs) are currently treated with second- or third-generation ALK inhibitors (ALK-TKIs), some patients respond durably to the first-generation ALK-TKI crizotinib. Objective:...
5.
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial
Levallet G, Dubois F, Elie N, Creveuil C, Brosseau S, Danel C, et al.
Lung Cancer . 2023 Jul; 182:107287. PMID: 37393757
Objectives: VEGF/VEGFR autocrine loop is a hallmark of pleural mesothelioma (PM). We thus assayed the prognostic and predictive values of VEGFR-2 [vascular endothelial growth factor receptor 2 or Flk-1] and...
6.
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
Wislez M, Mazieres J, Lavole A, Zalcman G, Carre O, Egenod T, et al.
J Immunother Cancer . 2022 Oct; 10(10). PMID: 36270733
Background: The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC). Methods: In a multicenter, single-arm, phase II trial, patients with IB (≥4 ...
7.
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies
Debieuvre D, Molinier O, Falchero L, Locher C, Templement-Grangerat D, Meyer N, et al.
Lancet Reg Health Eur . 2022 Sep; 22:100492. PMID: 36108315
Background: Long-term changes in lung cancer (LC) patients are difficult to evaluate. We report results from the French KBP-2020 real-life cohort. Methods: KBP-2020 was a prospective cohort that included all...
8.
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Barlesi F, Tomasini P, Karimi M, Michiels S, Raimbourg J, Daniel C, et al.
Clin Cancer Res . 2022 Jul; 28(18):4018-4026. PMID: 35802649
Purpose: Targeted therapies (TT) and immune checkpoint blockers (ICB) have revolutionized the approach to non-small cell lung cancer (NSCLC) treatment in the era of precision medicine. Their impact as switch...
9.
A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial
Maille E, Levallet J, Dubois F, Antoine M, Danel C, Creveuil C, et al.
Int J Cancer . 2022 Mar; 150(11):1889-1904. PMID: 35262190
The Hippo pathway effector YAP is dysregulated in malignant pleural mesothelioma (MPM). YAP's target genes include the secreted growth factor amphiregulin (AREG), which is overexpressed in a wide range of...
10.
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
Levy B, Barlesi F, Paz-Ares L, Bennouna J, Erman M, Felip E, et al.
Lung Cancer . 2022 Mar; 166:107-113. PMID: 35257949
Introduction: Afatinib and pembrolizumab have separately shown survival benefit in patients with squamous cell carcinoma (SqCC) of the lung, and there is biological rationale for concurrent inhibition of the programmed...